Understanding the mechanisms that impair anti-tumour adoptive cell therapy

Research Opportunity
PhD, Masters by Research, Honours
Department
Microbiology and Immunology
Location
Doherty Institute
Primary Supervisor Email Number Webpage
Professor Jose Villadangos j.villadangos@unimelb.edu.au (03) 9035 7684 Personal web page

Summary The aims of this project will be to identify genes that control the outcome of adoptive cell therapy, and characterise the interactions between T cells and the tumour.

Project Details

Tumour cells express neo-antigens that can be recognised by cytotoxic T lymphocytes (CTL). These tumour-specific CTL can be isolated, expanded and inoculated to kill cancer. Unfortunately, in many individuals the tumour ‘fights back’ and inactivates the infused CTL, compromising the therapy. Using a mouse model of lymphoma, we are performing studies to improve outcomes. Our goal is to apply our findings to the clinic and improve the efficacy of adoptive cell therapy. The aims of this project will be to identify genes that control the outcome of adoptive cell therapy, and characterise the interactions between T cells and the tumour.



Faculty Research Themes

Infection and Immunology

School Research Themes

Infection & Immunity



Research Opportunities

PhD, Masters by Research, Honours
Students who are interested in joining this project will need to consider their elegibility as well as other requirements before contacting the supervisor of this research

Graduate Research application

Honours application

Key Contact

For further information about this research, please contact a supervisor.

Department

Microbiology and Immunology

Research Group / Unit / Centre

Villadangos laboratory: Antigen presenting cells & molecules that initiate T cell immunity against pathogens and cancer

Research Node

Doherty Institute

MDHS Research library
Explore by researcher, school, project or topic.